Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

BAUS 2022: Navigating treatment decisions in non-metastatic castration-resistant prostate cancer (nmCRPC) patients

Nubeqa Header Image

Description

In this Bayer sponsored webinar, as part of the BAUS ‘Innovations in Urology’ series, Professor Noel Clarke from The Christie NHS Foundation Trust chairs this webinar exploring how urologists work as part of the wider multi-disciplinary team to deliver effective treatment for their nmCRPC patients. Professor Clarke provides an overview of the current treatment landscape for nmCRPC, exploring the latest clinical data and illustrates this through a pertinent case study of a patient with high risk nmCRPC.

Dr Mark Prentice from the Royal Free London NHS Foundation Trust delves into the influencing factors in treatment decisions for nmCRPC patients; exploring treatment options including darolutamide. Dr Prentice explores the profile of eligible patients and the importance of treating the right patient at the right time.

Ms Louisa Fleure from Guy’s and St Thomas’ NHS Foundation Trust examines what is important from a patient’s perspective, and the roles that different healthcare professionals play in addressing these treatment goals, as part of a wider multidisciplinary team approach with the aim of optimising treatment. The webinar concludes with an interactive Q&A chaired by Professor Clarke, addressing questions sent by the live audience.

This webinar is organised and funded by Bayer plc.

NUBEQA▼  Prescribing Information

Speakers
    • Noel ClarkeProfessor Noel Clarke

    Professor Noel Clarke is a Consultant Urological surgeon at The Christie and Salford Royal Hospitals and Honorary Professor of Urological Oncology at the University of Manchester. His specialist expertise is in genito-urinary cancer and complex pelvic and retroperitoneal malignancy. He is the director of The Christie/UoM Genitourinary Cancer Research Group and the FASTMAN National Centre of Excellence for Prostate cancer research. He is also joint clinical lead for the National Prostate Cancer Audit. Professor Clarke has co-authored over 270 scientific publications and eight book chapters on urological cancer. He has jointly planned and managed multiple national and international clinical trials.

    • Louisa FleureMs Louisa Fleure

    Louisa Fleure is Urology Consultant Nurse at Guy’s and St Thomas’ NHS Trust, London. She has authored several publications on urology and prostate cancer and presented at regional, national and international meetings on these topics. Louisa has served as trustee for the British Association of Urological Nurses (BAUN) and held the posts of Secretary, Treasurer and Conference Lead. Louisa’s hard work and dedication in the field of advanced prostate cancer has been widely acknowledged and has included: the Lynn Adams Award for leadership and innovation in cancer nursing (2014), runner up in the BJN urology nurse of the year (2015), 2016 BAUN Urology Team of the Year, finalist in oncology quality in Care Awards: prostate cancer survivorship team (2016), and the Nightingale Award (2018).

    Louisa Fleure was awarded The Urology Foundation/BAUN’s ‘Urology Nurse of the Year’ award in November 2019 for her work in providing information and support to men with advanced prostate cancer.

    Louisa is chair of the prostate Special Interest Group for the European Association of Urological Nurses.

    • Mark PrenticeDr Mark Prentice

    Dr Mark Prentice is a consultant clinical uro-oncologist working at The Royal Free Hospital in London. He is especially interested in the hormonal management of prostate cancer, novel radiotherapy techniques, advances in theranostics and quality of life metrics. Dr Prentice is keen to ensure that older patients have access to appropriate prostate cancer treatments and has co-authored international guidelines in this regard.

BAUS 2023: The role of Urologists in the MDT
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1319, February 2024
P3 Prostate Cancer Forum: Series Overview
NUBEQA®▼ (darolutamide) | Xofigo®▼ (radium-223 dichloride)
PP-NUB-GB-1318, February 2024
Evolving mCRPC treatment landscape in 2023
Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0505, February2024

PP-NUB-GB-1298 | February 2024